SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is trending as investors express significant frustration and skepticism toward the Board's decision to accept an all-cash acquisition offer, which many feel drastically undervalues the company's cash position, core drug assets, and future growth potential. The community is actively debating the merits of the deal, with some shareholders organizing to oppose the tender offer and others seeking legal avenues to challenge what they characterize as an unethical 'fire sale' by management.

MMTec, Inc. engages in the holding of an equity interest in MM Future. It operates through the Gujia, MM Future and HC Securities and MM Global. The Gujia, MM Future and HC Securities segment provide market data services and consulting services. The MM Global segment is involved in introducing a broker that clears all transactions through a clearing broker dealer and earns commission income, placement agent services fee, and other related income from customers. The company was founded on January 4, 2018 and is headquartered in Hong Kong.

Mmtec Inc

Mmtec Inc is generating significant market interest as traders speculate on potential short squeeze dynamics and the company's efforts to maintain its NASDAQ listing status. Community discussions are heavily focused on the stock's extreme volatility and its tendency to mirror past microcap momentum plays, with participants actively debating the risks of delisting against the possibility of aggressive rallies.

YD Bio Ltd. is a biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. It operates DNA methylation–based oncology testing programs under an LDT-first strategy and provides compliant life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology partners. The company’s offerings include cancer detection products, regenerative ophthalmology solutions, and exosome-based technologies. YD Bio was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.

YD Bio Ltd.

YDES is currently garnering significant attention from retail traders due to its status as a recent Nasdaq uplisting with a remarkably low float, leading to discussions about potential volatility and short-squeeze setups. The community is closely monitoring the stock's price action alongside its associated warrants, debating whether current valuations present a mispricing opportunity or a speculative trap.

Amtech Systems, Inc. engages in the manufacture of semiconductors and capital equipment. It operates through the Semiconductor and Material and Substrate segments. The Semiconductor segment involves the designing, manufacturing, selling, and servicing of thermal processing equipment and related controls for use by semiconductor manufacturers, and in electronics, automotive, and other industries. The Material and Substrate segment produces consumables and machinery for lapping and polishing materials, such as sapphire substrates, optical components, silicon wafers, and numerous types of crystal materials, ceramics, and metal components. The company was founded by Jong S. Whang in October 1981 and is headquartered in Tempe, AZ.

Amtech Systems Inc.

Amtech Systems is gaining momentum as investors eye its strategic role in the AI-driven semiconductor supply chain, specifically through its exposure to advanced packaging and wafer substrate fabrication. While the community remains optimistic about the company's long-term growth potential and turnaround narrative, discussions are increasingly balanced by caution regarding recent earnings performance and sector-wide cyclical risks.

LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. Its product offers automation and customization options for astigmatism treatment planning and other steps of the refractive cataract surgery procedure. The company was founded by Scott Addyman, Randy W. Frey, and Ronald R. Krueger in 2004 and is headquartered in Orlando, FL.

LENSAR Inc

LENSAR Inc. shares are under significant pressure following the mutual termination of its merger agreement with Alcon, a decision prompted by mounting regulatory opposition from the FTC. The community is actively debating the company's standalone future, weighing concerns over operational liquidity and intense market competition against the potential durability of its recurring revenue model and ALLY system adoption.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is trending due to its unique 'PvE' (Player-versus-Environment) narrative, which emphasizes long-term community conviction over short-term speculative trading. Supporters are actively highlighting the project's 'Airlock' mechanismwhere nearly half of the supply is voluntarily lockedas proof of a committed, cult-like movement that is actively outperforming typical market volatility.

Ethereum Classic

Ethereum Classic is experiencing renewed community focus as investors speculate on a long-awaited breakout, with many sentiment-driven discussions highlighting the contrast between the token's historical performance and its current suppressed price action. Traders are actively debating the timing of a potential trend reversal, frequently citing broader crypto market catalysts and comparing its utility to other established proof-of-work assets.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is currently rallying on optimism surrounding potential ETF approval and its dominant position as a leading decentralized perpetual exchange. The community is actively discussing its rapid growth in trading volume and its role as a key infrastructure player in the broader decentralized finance ecosystem.

Maulcoin

Maulcoin is trending as the community celebrates the restoration of its ticker symbol and anticipates the upcoming release of a price chart. Supporters are actively engaging in community-led growth strategies, framing the project as an honest, long-term alternative to typical pump-and-dump meme coins.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as a long-standing satirical project that has transitioned onto the Solana network, with the community positioning it as a cultural successor to early Bitcoin lore. Supporters are actively discussing its 15-year history and perceived potential for generational wealth, while debates continue between those dismissing it as a meme-driven joke and those convinced it represents a unique opportunity in the current market cycle.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Conduit Pharmaceuticals Inc. (CDT) tumbled 17% on Wednesday after the company announced that it has entered into a development agreement with privately held animal health company Manoira Corporation.As part of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://s3.amazonaws.com/b2icontent.irpass.cc/2892/rl146071.pdf">agreement</a>, Manoira will evaluate Conduit's clinical-stage candidates AZD1656 and AZD5658 in animal health indications.Manoira will initially focus on the evaluation of AZD1656 in animal Osteoarthritis. Osteoarthritis is a degenerative joint condition in companion animals.The collaboration will help Conduit accelerate its understanding of AZD1656's mechanism of action, safety profile, and potential efficacy across species, while retaining ownership of all data and intellectual property generated for human applications.The partnership, Conduit said, opens potential new revenue streams in the high-growth veterinary market.The parties will determine any future financial benefits and implications upon review of the results of the evaluations and how to proceed as a result of any such findings, Conduit said.Manoira has agreed to fund all the developmental activities of the collaboration, and Conduit has agreed to issue Manoira an up-front consideration of $500,000. Conduit’s consideration will be settled through the issuance of 154,799 shares of common stock at $3.23, or its closing price on Tuesday.On Stocktwits, retail sentiment around CDT stayed unmoved within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1264/128;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_04_at_11_58_35_AM_png_7bfe8d0833.webp" alt="CDT's Sentiment Meter and Message Volume as of 12:00 p.m. ET on June 4, 2025 | Source: Stocktwits" width="1264" height="128"><figcaption>CDT's Sentiment Meter and Message Volume as of 12:00 p.m. ET on June 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they bought the stock during the dip.<stembedurl>https://stocktwits.com/BankingBig/message/616778690</stembedurl>Another sees it rising back to over $10.<stembedurl>https://stocktwits.com/LetsgoDudeszi/message/616768852</stembedurl><a href="https://stocktwits.com/symbol/CDT">CDT stock</a> is down by approximately 98% this year and has lost most of its value over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-inks-deal-with-graphiteone/chkuKwsRbwU">Lucid Inks Deal With Graphite One To Strengthen Local Graphite Supply Chain: Retail Sees Stock Hitting $3 To $5 In Coming Months</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Conduit Pharmaceuticals Enters Development Agreement With Manoira To Test Drugs In Animals: Retail Sees Stock Above $10

Manoira will initially focus on the evaluation of AZD1656 in animal Osteoarthritis.

Equity

Shares of Conduit Pharmaceuticals Inc. (CDT) dropped 5% on Friday morning after the company’s board <a target="_blank" rel="noopener noreferrer nofollow" href="https://s3.amazonaws.com/b2icontent.irpass.cc/2892/rl145666.pdf">approved</a> a 1-for-15 reverse stock split of its common stock.Earlier, shareholders approved the stock split proposal in a meeting on May 5, leaving it upon the board to determine the exact split ratio.The company said the reverse stock split will become effective on May 19 at 5:00 p.m. ET, and the stock will start trading on a reverse stock-split adjusted basis at market open on May 20.On May 19 evening, every 15 shares of the firm’s issued and outstanding common stock will be combined into one share, reducing the number of outstanding shares of common stock to about 755,900.The company said no fractional shares will be issued in connection with the split, and those entitled to a fractional share will instead receive a proportional cash payment.Earlier this month, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://s3.amazonaws.com/sec.irpass.cc/2892/0001641172-25-010405.htm">flagged</a> doubts regarding its ability to continue as a going concern for at least the next 12 months.It said management has determined it does not have sufficient cash and other sources of liquidity to fund its current business plan, adding that it had cash and cash equivalents of only $2.1 million as of the end of the first quarter.On Stocktwits, retail sentiment around Conduit Pharmaceuticals remained unmoved within the ‘bearish’ territory over the past 24 hours while message volume remained at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_16_at_10_29_21_AM_png_0ccaac1374.webp" alt="CDT's Sentiment Meter and Message Volume as of 10:30 a.m. ET on May 16, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>CDT's Sentiment Meter and Message Volume as of 10:30 a.m. ET on May 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user, however, expressed skepticism about the stock’s performance.<stembedurl>https://stocktwits.com/rkfrkf/message/614872963</stembedurl>The shares closed at over $1 last in early April.<a href="https://stocktwits.com/symbol/CDT">CDT stock</a> is down 95% this year and has lost nearly all of its value over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/trump-says-tariff-deals-with-other-countries-in-two-three-weeks/chiwIazRbnt">Trump Says Tariff Deals With Other Nations To Be Set Within 2 To 3 Weeks: ‘I Think We’re Going To Be Very Fair’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Conduit Pharma Stock Drops On Reverse Stock Split Announcement: Retail’s Pessimistic

The company said that the reverse stock split will become effective on May 19 at 5:00 p.m. ET, and the stock will start trading on a reverse stock-split adjusted basis at market open on May 20. 

Conduit Pharma Stock Drops On Reverse Stock Split Announcement: Retail’s Pessimistic 

The company said that the reverse stock split will become effective on May 19 at 5:00 p.m. ET, and the stock will start trading on a reverse stock-split adjusted basis at market open on May 20. 


CDT Equity, Inc. engages in facilitating the development and commercialization of clinical assets. The company was founded by David Joszef Tapolczay and Freda C. Lewis-Hall in October 2021 is headquartered in Naples, FL.

CDT
Conduit Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CDT News

CDTConduit Pharmaceuticals Inc